KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.

Safia K Ahmed, Odion Binitie, Mark Krailo, Daniel J Indelicato, Alexandra K Callan, Natalie DelRocco, Allen Buxton, Paul Chuba, Alexander Christ, Robert Lor Randall, Helen Nadel, Bruce Pawel, Damon R Reed, Richard G Gorlick, Steven G DuBois, Katherine A Janeway, Patrick J Leavey, Leo Mascarenhas, Nadia N I Laack

Int J Radiat Oncol Biol Phys 125(2) 521-529

PMID41285272
PMCIDPMC13052378
DOI10.1016/j.ijrobp.2025.11.010
发表日期2025-11-24
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Local therapy (LT) is a critical component of curative treatment for Ewing sarcoma (ES). This analysis evaluated clinical and treatment variables associated with local failure (LF) risk for nonmetastatic patients with ES. METHODS AND MATERIALS: AEWS1031 was a phase 3 randomized trial comparing 2 interval-compressed chemotherapy regimens. Patients who completed induction chemotherapy and started LT of the primary tumor site were analyzed. LT was surgery alone (S), definitive radiation therapy (RT), or surgery and RT (S+RT), and was determined by the treating investigator. The primary endpoint was the cumulative incidence of LF estimated from the time LT was started. Elastic net penalization was used to identify predictors associated with the cause-specific hazard rates of LF. RESULTS: Five hundred eighty-eight patients started LT. Tumor sites were extremity (40%), axial (27%), pelvis (18%), and extraosseous (15%). LT was S (54%), RT (27%), and S+RT (18%). With a median follow-up of 67.6 months, the 5-year cumulative incidence of LF for all patients was 6%. LF incidence was 5% for S, 8.4% for RT, and 5.6% for S+RT (P = .47). LF incidence was 3.5% for extremity, 8.7% for pelvis, 7.7% for axial, and 6.3% for extraosseous (P = .09). LF incidence was higher for tumors ≥200 mL (11.3%) compared with tumors <200 mL (3.9%; P < .01). On multivariable modeling, increasing age at enrollment (cause-specific relative hazard ratio [csRHR] 1.04/y) and increasing maximum tumor dimension (csRHR 1.08/cm) were suggestive of a higher incidence of LF. By tumor subsite, axial tumors were associated with the highest risk of LF (csRHR 1.17) and extremity tumors with the lowest risk (csRHR 0.50). CONCLUSIONS: We report the lowest LF incidence to date for prospective ES trials. Large tumors, older age, and axial tumor subsite were associated with higher LF incidence, indicating further efforts are needed to identify the highest-risk subset most likely to benefit from improved LT strategies.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 2.

Fig. 2. (A) Five-year cumulative incidence of local failure by local treatment modality. (B) Five-year cumulative incidence of local failure by tumor site. (C) Five-year cumulative incidence of local failure by tumor volume. (D) Five-year cumulative incidence of local failure by tumor size in maximum dimension.

A

cumulative incidence of local failure

Fig. 2. · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 3:off origin start
查看结果
B

cumulative incidence of local failure

Fig. 2. · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel B 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

cumulative incidence of local failure

Fig. 2. · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

cumulative incidence of local failure

Fig. 2. · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1.Fig. 1. Consort diagram of AEWS1031 local therapy analysis cohort. Abbreviations: IE = ifosfamide/etoposide; VDC = vincristine/doxorubicin/cyclophosphamide; VTC = vincristine/topotecan/cyclophosphamide.
非 KM Figure